Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by inthnoon Sep 07, 2023 11:02pm
216 Views
Post# 35625455

RE:RE:RE:RE:pan can protocols

RE:RE:RE:RE:pan can protocols
Hello Noteable and I hope you are right as I remember Kirk saying that at the cc presentation on the Friday and then on Monday August 14th (3 days later) for the quarterly cc this is a quote from Matt as I have the transcript.I had the transcript for the Friday fireside chat with Cannacord but cannot find that but I do agree that Kirk said at that time that he expected September.

Our plan for this indication is to finalize agreements with the Precision Promise team by the fourth quarter of this year, and we expect to open the investigational treatment of pela a checkpoint inhibitor gemcitabine and nab-paclitaxel in early 2024.

I guess we will all know soon enough and hope that there is enough information given in regards to the agreement to add more excitement to the company with hopefully the announcement of the ci they are going to use or maybe even a partner although that could come at a later date.
<< Previous
Bullboard Posts
Next >>